JNJ Q3 operational sales rise 6%, full-year guidance lifted to $100.7B

What happened

Johnson & Johnson reported Q3 2026 operational sales growth of 6% year over year, indicating resilience despite the ongoing STELARA biosimilar erosion and the July 1 CVS formulary shift. Management raised full-year operational sales guidance to a midpoint of $100.7 billion, up from prior expectations, signaling confidence in the growth drivers such as DARZALEX, CARVYKTI, and TREMFYA. The update does not provide granularity on Innovative Medicine segment growth or whether immunology declines were offset by oncology and other franchises, leaving the core thesis's key checkpoints partially unverified. Talc litigation remains an open risk, with no new disclosure in this report; the master report's concerns about potential liability creep and expert testimony rulings are unaddressed. Overall, the top-line momentum is encouraging but insufficient to fully resolve the dual overhangs of immunology transition and talc exposure, warranting continued monitoring.

Implication

The 6% operational growth and raised guidance support the base case that oncology and other growth drivers can offset STELARA erosion, reducing the probability of the bear scenario. However, without specific immunology metrics, it is unclear if the CVS formulary change caused a sharper-than-expected decline that was masked by other segments or favorable currency. The absence of talc updates means the most significant asymmetric downside risk remains unchanged, and the company's inability to estimate losses beyond accruals continues to limit margin of safety. Investors should monitor the Q3 earnings call transcript for management commentary on STELARA, gross-to-net, and any talc accrual changes; a lack of incremental talc charges would be a positive signal. Until clearer evidence of immunology stabilization and bounded talc exposure emerges, the risk-reward does not support an upgrade from WAIT, and any price strength toward the trim level should be used to reduce exposure.

Thesis delta

The original thesis emphasized waiting for Q2-Q3 FY2026 proof of immunology stabilization; the Q3 operational growth of 6% and raised guidance provide partial confirmation that top-line offset is working. However, the update lacks segment-level detail and any litigation disclosure, so the thesis's core uncertainty about talc and STELARA trajectory persists. The balance of evidence shifts slightly positive but is not sufficient to alter the WAIT rating or the attractive entry point.